Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials

Diabetologia. 2020 Nov;63(11):2482-2485. doi: 10.1007/s00125-020-05273-7. Epub 2020 Sep 21.

Authors

Jin J Zhou^{1

2}, Ruth Coleman³, Rury R Holman³, Peter Reaven⁴

Affiliations

¹ Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA. [email protected].
² Carl T. Hayden Phoenix VA Health Care System (111E), Phoenix, AZ, USA. [email protected].
³ Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
⁴ Carl T. Hayden Phoenix VA Health Care System (111E), Phoenix, AZ, USA.

No abstract available

Keywords: Intensive glycaemic control; Long-term glycaemic variability; Microvascular complications; Nephropathy; Type 2 Diabetes.

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 2 / drug therapy
Diabetes Mellitus, Type 2 / metabolism*
Glycated Hemoglobin / metabolism*
Humans
Hypoglycemic Agents / therapeutic use

Substances

Blood Glucose
Glycated Hemoglobin A
Hypoglycemic Agents

Grants and funding